Ваша жизнь в ваших руках. Как понять, победить и предотвратить рак груди и яичников - Джейн Плант (2012)

71. Maruuchi, T. and others, 1998. Effects of gonadotropin-releasing hormone agonist on rat ovarian adenocarcinoma cell lines in vitro and in vivo .Japanese Journal of Cancer Research, 89 (9), 977–983; Kuroda, H. and others, 1998. Human chorionic gonadotrophin (hCG) inhibits cisplatin-induced apoptosis in ovarian cancer cells: possible role of up-regulation of IGF-1 by hCG. Int J Cancer, 76 (4), 571–578; Kurbacher, C.M. and others, 1995. Influence of luteinising hormone on cell growth and С A 125 secretion of primary epithelial ovarian carcinomas in vitro. Tumour Biology, 16 (6), 374–384; Manetta, A. and others, 1995. Inhibition of growth of human ovarian cancer in nude mice by luteinising hormone-releasing hormone antagonist Cetrorelix (SB-75). Fertility and Sterility, 63 (2), 282–287.

72. Reiter, E. and others, 1999. Effects of pituitary hormones on the prostate. Prostate, 38 (2), 159–165; Lamharzi, N. and others, 1998. Luteinising hormone-releasing hormone (LH-RH) antagonist Cetrorelix inhibits growth of DU-145 human androgen-independent prostate carcinoma in nude mice and suppresses the levels and mRNA expression of IGF-2 in tumors. Regulatory Peptides, 77 (113), 185–192; Jungwirth, A. and others, 1997. Luteinising hormone-releasing hormone (LH-RH) antagonist Cetrorelix (SB-75) and bombesin antagonist RC-3940-2 inhibit the growth of androgen-independent PC-3 prostate cancer in nude mice. Prostate, 32 (3), 164–172; Maeza-wa, H. and others, 1997. Potentiating effect of buserelin ace-täte, an LHRH agonist on the proliferation of ventral prostatic epithelial cells in testosterone-treated castrated rats. Int J Urol,

4 (4), 411–416; Using, АЖ and others, 1993. Serological precursors of cancer serum hormones and risk of subsequent prostate cancer. Cancer Epidemiol Biomarkers Prev, 2 (1), 27–32; Garde, S. and others, 1993. Effect of prostatic inhibiting peptide on prostate cancer cell growth in vitro and in vivo. Prostate, 7 (2), 183–194.

73. Bosland, M.C., 1996. Hormonal factors in carcinogenesis of the prostate and testis in humans and in animal models. Progress in Clinical and Biological Research, 394, 309–352.

74. Chapman, S. and others, 1992. Changes in adult cigarette consumption per head in 128 countries, 1986–1990. Tobacco Control, 1,281–284.

75.

76. Chapman, S. and others, 1992. Changes in adult cigarette consumption per head in 128 countries, 1986–1990. Tobacco Control,, 1.281–284.

77.

78.

79. Underwood, L.E., D’Ercole, J.A. and Van Wyk, J.J., 1980. So-matomedin-C and the assessment of growth. Ped ClinN Amer,

27, 4, 771–782, and Perdue, J.E 1984. Chemistry, structure and function of insulin-like growth factors and their receptors: a review. Can J Вiochem Cell Bio, 62, 1237–1245.

80.

81. Pollack, Michael, 2003. Cancer, aging and IGF physiology. Meeting of the Royal Society of Medicine in London in October 2003, entitled „Biology of IGF-I: its interaction with insulin in health and malignant statescc.

82. Lonning, Per Eystein, 2003. IGF-I and breast cancer. Meeting of the Royal Society of Medicine in London in October 2003, entitled „Biology of IGF-I: its interaction with insulin in health and malignant statescc.

83. Yee, Doug, 2003. Targeting the IGF system for anti-tumour therapy. Meeting of the Royal Society of Medicine in London in October 2003, entitled „Biology of IGF-I: its interaction with insulin in health and malignant statescc.

84. Pollack, Michael, 2003. Cancer, aging and IGF physiology. Meeting of the Royal Society of Medicine in London in October 2003, entitled ‘Biology of IGF-I; its interaction with insulin in health and malignant states’.

85. Holly, Jeff, 1998. Insulin-like growth factor-1 and new opportunities for cancer prevention. Lancet, 351, 9113, 9 May, 1373–1375.